N-of-1 Trials in Cancer Drug Development
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Lars Buschhorn(National Center for Tumor Diseases), Adam Wahida(National Center for Tumor Diseases), Andreas Schneeweiß(Heidelberg University)
Cited by 43
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766